Vaccitech plc (USD) Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Vaccitech plc (USD) Passive

The SchrOedinger Building, Oxford, GB, OX4 4GE

Stock Price USD

Price Change

Last Dividend USD

VACC's stock peer is ACET (Adicet Bio, Inc.)

VACC's stock peer is ACHL (Achilles Therapeutics plc)

VACC's stock peer is ANEB (Anebulo Pharmaceuticals, Inc.)

VACC's stock peer is ASMB (Assembly Biosciences, Inc.)

VACC's stock peer is CCCC (C4 Therapeutics, Inc.)

VACC's stock peer is CGEM (Cullinan Oncology, Inc.)

VACC's stock peer is CSBR (Champions Oncology, Inc.)

VACC's stock peer is CTMX (CytomX Therapeutics, Inc.)

VACC's stock peer is CYT (Cyteir Therapeutics, Inc.)

VACC's stock peer is DSGN (Design Therapeutics, Inc.)

VACC's stock peer is EWTX (Edgewise Therapeutics, Inc.)

VACC's stock peer is GRPH (Graphite Bio, Inc.)

VACC's stock peer is MGTA (Magenta Therapeutics, Inc.)

VACC's stock peer is MNOV (MediciNova, Inc.)

VACC's stock peer is MOLN (Molecular Partners AG)

VACC's stock peer is NLTX (Neoleukin Therapeutics, Inc.)

VACC's stock peer is RVMD (Revolution Medicines, Inc.)

VACC's stock peer is SPRO (Spero Therapeutics, Inc.)

VACC's stock peer is STOK (Stoke Therapeutics, Inc.)

VACC's stock peer is TALS (Talaris Therapeutics, Inc.)

VACC's stock peer is THRD (Third Harmonic Bio, Inc.)

VACC's stock peer is TIL (Instil Bio, Inc.)

VACC's stock peer is TYRA (Tyra Biosciences, Inc.)

VACC's stock peer is VOR (Vor Biopharma Inc.)

Healthcare Biotechnology

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions